Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNR NASDAQ:CDNA OTCMKTS:EKTAY NYSE:NVTA NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNRBurning Rock Biotech$8.58+2.0%$7.40$2.18▼$11.12$92.28M0.9131,296 shs50,635 shsCDNACareDx$14.70-0.5%$13.41$10.96▼$32.97$782.48M2.281.20 million shs908,200 shsEKTAYElekta$5.26-1.6%$4.97$4.36▼$7.13$1.94B1.112,368 shs1,943 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shs75 shsVCYTVeracyte$34.32+3.3%$28.15$22.61▼$47.32$2.70B2.071.14 million shs742,209 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNRBurning Rock Biotech+0.42%-6.05%-11.55%+127.53%+144.26%CDNACareDx+3.29%+9.16%+27.66%-22.43%-49.52%EKTAYElekta+2.57%+2.67%+7.21%+8.58%-19.46%NVTAInvitae0.00%0.00%0.00%0.00%0.00%VCYTVeracyte+4.40%+4.30%+12.38%+25.92%-1.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNRBurning Rock Biotech$8.58+2.0%$7.40$2.18▼$11.12$92.28M0.9131,296 shs50,635 shsCDNACareDx$14.70-0.5%$13.41$10.96▼$32.97$782.48M2.281.20 million shs908,200 shsEKTAYElekta$5.26-1.6%$4.97$4.36▼$7.13$1.94B1.112,368 shs1,943 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shs75 shsVCYTVeracyte$34.32+3.3%$28.15$22.61▼$47.32$2.70B2.071.14 million shs742,209 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNRBurning Rock Biotech+0.42%-6.05%-11.55%+127.53%+144.26%CDNACareDx+3.29%+9.16%+27.66%-22.43%-49.52%EKTAYElekta+2.57%+2.67%+7.21%+8.58%-19.46%NVTAInvitae0.00%0.00%0.00%0.00%0.00%VCYTVeracyte+4.40%+4.30%+12.38%+25.92%-1.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNRBurning Rock Biotech 0.00N/AN/AN/ACDNACareDx 2.57Moderate Buy$25.5073.47% UpsideEKTAYElekta 1.75ReduceN/AN/ANVTAInvitae 0.00N/AN/AN/AVCYTVeracyte 2.70Moderate Buy$40.9019.19% UpsideCurrent Analyst Ratings BreakdownLatest EKTAY, BNR, CDNA, VCYT, and NVTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/16/2025EKTAYElektaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/12/2025CDNACareDxBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.009/3/2025EKTAYElektaUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell8/26/2025CDNACareDxWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform8/8/2025VCYTVeracyteMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetUnderweight$28.008/8/2025CDNACareDxWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$19.00 ➝ $14.007/18/2025CDNACareDxCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $26.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNRBurning Rock Biotech$536.30M0.17N/AN/A$7.39 per share1.16CDNACareDx$333.79M2.34$1.40 per share10.52$7.06 per share2.08EKTAYElekta$1.71B1.14$0.61 per share8.57$2.58 per share2.04NVTAInvitae$481.58M0.00N/AN/A$0.42 per share0.00VCYTVeracyte$479.13M5.63$1.12 per share30.70$15.17 per share2.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNRBurning Rock Biotech-$47.49M-$1.90N/A∞N/A-26.04%-23.61%-15.73%N/ACDNACareDx$52.55M$1.0214.41N/AN/A17.97%18.03%12.88%11/3/2025 (Estimated)EKTAYElekta$22.37M$0.0687.7512.24N/A1.40%11.49%3.65%11/26/2025 (Estimated)NVTAInvitae-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/AVCYTVeracyte$24.14M$0.33103.9947.66N/A5.50%6.07%5.53%11/5/2025 (Estimated)Latest EKTAY, BNR, CDNA, VCYT, and NVTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/8/2025Q2 2025BNRBurning Rock BiotechN/A-$0.15N/A-$0.15N/A$20.74 million8/28/2025Q1 2026EKTAYElektaN/A$0.03N/A$0.03N/A$379.64 million8/6/2025Q2 2025CDNACareDx$0.12-$0.16-$0.28-$0.16$90.72 million$90.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNRBurning Rock BiotechN/AN/AN/AN/AN/ACDNACareDxN/AN/AN/AN/AN/AEKTAYElekta$0.122.28%N/A200.00%N/ANVTAInvitaeN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ALatest EKTAY, BNR, CDNA, VCYT, and NVTA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/3/2025EKTAYElekta$0.07442.89%9/8/20259/9/20259/26/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNRBurning Rock BiotechN/A3.222.97CDNACareDxN/A3.303.00EKTAYElekta0.631.050.82NVTAInvitaeN/A2.392.25VCYTVeracyteN/A5.435.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNRBurning Rock Biotech30.03%CDNACareDxN/AEKTAYElektaN/ANVTAInvitae61.28%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipBNRBurning Rock Biotech30.30%CDNACareDx4.40%EKTAYElekta41.28%NVTAInvitae0.74%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNRBurning Rock Biotech1,39010.76 million7.50 millionNot OptionableCDNACareDx74053.23 million50.89 millionOptionableEKTAYElekta4,718368.59 million216.44 millionNot OptionableNVTAInvitae1,700267.01 million284.37 millionOptionableVCYTVeracyte79078.67 million77.57 millionOptionableEKTAY, BNR, CDNA, VCYT, and NVTA HeadlinesRecent News About These CompaniesAQR Capital Management LLC Lowers Stock Position in Veracyte, Inc. $VCYTSeptember 15, 2025 | marketbeat.comVeracyte, Inc. $VCYT Stake Trimmed by Great Lakes Advisors LLCSeptember 13, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) CEO Sells 7,667 SharesSeptember 10, 2025 | marketbeat.comVeracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual MeetingSeptember 10, 2025 | finance.yahoo.comVeracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comMarc Stapley Sells 7,667 Shares of Veracyte (NASDAQ:VCYT) StockSeptember 9, 2025 | insidertrades.comVeracyte, Inc. (NASDAQ:VCYT) Receives $40.90 Average Target Price from AnalystsSeptember 9, 2025 | americanbankingnews.comVeracyte, Inc. $VCYT Stake Lifted by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comBridgeway Capital Management LLC Sells 41,300 Shares of Veracyte, Inc. $VCYTSeptember 8, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 8, 2025 | marketbeat.comRaymond James Financial Inc. Purchases 172,010 Shares of Veracyte, Inc. $VCYTSeptember 6, 2025 | marketbeat.comPDT Partners LLC Sells 27,566 Shares of Veracyte, Inc. $VCYTSeptember 5, 2025 | marketbeat.comMagnetar Financial LLC Invests $651,000 in Veracyte, Inc. $VCYTSeptember 3, 2025 | marketbeat.comTrexquant Investment LP Sells 10,790 Shares of Veracyte, Inc. $VCYTSeptember 3, 2025 | marketbeat.comHsbc Holdings PLC Buys 10,618 Shares of Veracyte, Inc. $VCYTSeptember 2, 2025 | marketbeat.comRafferty Asset Management LLC Has $3.29 Million Stock Position in Veracyte, Inc. $VCYTSeptember 1, 2025 | marketbeat.comNorthern Trust Corp Trims Stake in Veracyte, Inc. $VCYTSeptember 1, 2025 | marketbeat.comDriehaus Capital Management LLC Purchases 167,604 Shares of Veracyte, Inc. $VCYTAugust 31, 2025 | marketbeat.comRussell Investments Group Ltd. Sells 28,644 Shares of Veracyte, Inc. $VCYTAugust 31, 2025 | marketbeat.comNext Century Growth Investors LLC Lowers Stake in Veracyte, Inc. $VCYTAugust 30, 2025 | marketbeat.comVeracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceAugust 29, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEKTAY, BNR, CDNA, VCYT, and NVTA Company DescriptionsBurning Rock Biotech NASDAQ:BNR$8.57 +0.17 (+1.96%) As of 01:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.CareDx NASDAQ:CDNA$14.70 -0.07 (-0.47%) As of 01:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Elekta OTCMKTS:EKTAY$5.26 -0.09 (-1.61%) As of 12:33 PM EasternElekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.Invitae NYSE:NVTAInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.Veracyte NASDAQ:VCYT$34.34 +1.11 (+3.33%) As of 01:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Joby's Stock Is Quiet, But Its Commercial Engine Is In Overdrive NIO's New Dawn: Why Wall Street's Bullish Turn Signals a Comeback Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
